This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lortholary, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lortholary, O.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2007, p. 3378-3380, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.00496-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vitro Susceptibility to Posaconazole of 1,903 Yeast Isolates Recovered in France from 2003 to 2006 and Tested by the Method of the European Committee on Antimicrobial Susceptibility Testing{triangledown}

Olivier Lortholary,1,2* Eric Dannaoui,1,7 Dorothée Raoux,1 Damien Hoinard,1 Annick Datry,3 André Paugam,4 Jean-Louis Poirot,5 Claire Lacroix,6 Françoise Dromer,1 the YEASTS Group

Centre National de Référence Mycologie et Antifongiques, Unité de Mycologie Moléculaire, CNRS URA3012, Institut Pasteur,1 Université René Descartes, Hôpital Necker-Enfants Malades, Service des Maladies Infectieuses et Tropicales, Centre d'Infectiologie Necker-Pasteur,2 Hôpital Pitié-Salpétrière,3 Université René Descartes, Hôpital Cochin,4 Hôpital Saint Antoine,5 Hôpital Saint Louis,6 Université René Descartes, Hôpital Européen Georges Pompidou, Unité de Parasitologie-Mycologie Paris, France7

Received 13 April 2007/ Returned for modification 12 May 2007/ Accepted 11 June 2007

The posaconazole MIC90 for 1,903 yeast isolates from France was 1 µg/ml (range, ≤0.015 to 8 µg/ml). Ninety percent of isolates with fluconazole MICs of ≥8 µg/ml (n = 509) and 90% of those with voriconazole MICs of ≥2 µg/ml (n = 80) were inhibited by 2 and 8 µg/ml of posaconazole, respectively.

* Corresponding author. Mailing address: Centre National de Référence Mycologie et Antifongiques, Unité de Mycologie Moléculaire, CNRS URA3012, Institut Pasteur, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France. Phone: 33 1 45 68 83 55. Fax: 33 1 45 68 84 20. E-mail: olortho{at}pasteur.fr

{triangledown} Published ahead of print on 18 June 2007.

Antimicrobial Agents and Chemotherapy, September 2007, p. 3378-3380, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.00496-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pfaller, M. A., Messer, S. A., Boyken, L., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2008). Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance Program. J. Clin. Microbiol. 46: 551-559 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»